OR51A4: Potential Drug Target and Cancer, Neurodegerative Diseases and Autoimmune Disorders
OR51A4: Potential Drug Target and Cancer, Neurodegerative Diseases and Autoimmune Disorders
OR51A4 (O51A4_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, lungs, heart, kidneys, and intestines. It is a member of the OR51 family of proteins, which are involved in various cellular processes, including cell signaling, migration, and invasion. OR51A4 has been identified as a potential drug target and has been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
The OR51A4 protein is composed of 51 amino acid residues and has a calculated molecular weight of 61.1 kDa. It is expressed in a variety of tissues, including the brain, lungs, heart, kidneys, and intestines, and is localized to the cell surface. OR51A4 is involved in several cellular processes, including cell signaling, migration, and invasion.
OR51A4 has been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, OR51A4 has been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. OR51A4 has also been shown to be involved in the development of cancer, by promoting the growth and survival of cancer cells.
In addition to its role in disease, OR51A4 is also a potential drug target. Researchers have identified several potential drugs that can inhibit OR51A4 function, and these drugs have been shown to have potential therapeutic benefits in a variety of diseases, including cancer, neurodegenerative diseases , and autoimmune disorders.
One of the most promising drugs that has been identified as a potential inhibitor of OR51A4 is a small molecule called TK-5120. TK-5120 is a compound that can inhibit the activity of OR51A4, by blocking its ability to promote cell growth and migration. TK-5120 has been shown to be effective in preclinical studies in treating a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
Another potential inhibitor of OR51A4 is a drug called Imprastamol. Imprastamol is a compound that can inhibit the activity of OR51A4, by blocking its ability to promote cell growth and migration. Imprastamol has been shown to be effective in preclinical studies in treating a variety of diseases , including cancer, neurodegenerative diseases, and autoimmune disorders.
In addition to these drugs, researchers are also exploring the use of small molecules and other compounds as potential inhibitors of OR51A4. These compounds can be synthesized using various methods, and can be tested for their effectiveness in preclinical studies.
Overall, OR51A4 is a protein that is involved in several cellular processes, including cell signaling, migration, and invasion. It has been shown to play a role in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In addition, OR51A4 is also a potential drug target, and several potential inhibitors have been identified that can block its activity. Further research is needed to fully understand the role of OR51A4 in disease and to develop effective treatments.
Protein Name: Olfactory Receptor Family 51 Subfamily A Member 4
Functions: Odorant receptor
The "OR51A4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR51A4 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
OR51A6P | OR51A7 | OR51B2 | OR51B4 | OR51B5 | OR51B6 | OR51C1P | OR51D1 | OR51E1 | OR51E2 | OR51F1 | OR51F2 | OR51G1 | OR51G2 | OR51H1 | OR51I1 | OR51I2 | OR51J1 | OR51L1 | OR51M1 | OR51Q1 | OR51S1 | OR51T1 | OR51V1 | OR52A1 | OR52A4P | OR52A5 | OR52B2 | OR52B4 | OR52B6 | OR52D1 | OR52E1 | OR52E2 | OR52E4 | OR52E5 | OR52E6 | OR52E8 | OR52H1 | OR52I1 | OR52I2 | OR52J3 | OR52K1 | OR52K2 | OR52K3P | OR52L1 | OR52M1 | OR52N1 | OR52N4 | OR52N5 | OR52R1 | OR52W1 | OR52Z1P | OR56A1 | OR56A3 | OR56A4 | OR56A5 | OR56B1 | OR56B4 | OR5A1 | OR5A2 | OR5AC1 | OR5AC2 | OR5AK2 | OR5AK4P | OR5AN1 | OR5AP2 | OR5AR1 | OR5AS1 | OR5AU1 | OR5B12 | OR5B17 | OR5B2 | OR5B21 | OR5B3 | OR5BA1P | OR5C1 | OR5D13 | OR5D14 | OR5D16 | OR5D17P | OR5D18 | OR5E1P | OR5F1 | OR5H1 | OR5H14 | OR5H15 | OR5H2 | OR5H4P | OR5H6 | OR5I1 | OR5K1 | OR5K2 | OR5K3 | OR5K4 | OR5L1 | OR5L2 | OR5M1 | OR5M10 | OR5M11 | OR5M3
